Sun Yat-sen University
Clinical trials sponsored by Sun Yat-sen University, explained in plain language.
-
Radiation boost could extend lives in High-Risk prostate cancer
Disease control OngoingThis study compares two approaches for men whose prostate cancer has spread to nearby lymph nodes after surgery. Researchers want to see if adding pelvic radiation to standard hormone therapy helps keep the cancer from returning longer than hormone therapy alone. About 374 partic…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 02, 2026 02:12 UTC
-
New drug duo aims to stop aggressive kidney Cancer's comeback
Disease control OngoingThis study is testing whether a combination of two drugs can help prevent a less common type of kidney cancer from returning after surgery. The treatment involves an IV medication and a daily pill given for up to one year to 40 patients at high risk of their cancer coming back. T…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 02, 2026 02:11 UTC
-
New drug duo aims to fight tough uterine cancer
Disease control OngoingThis study is testing whether a new combination of two drugs, cadonilimab and lenvatinib, can help control advanced endometrial cancer that has continued to grow after standard chemotherapy. It will involve about 32 patients to see how well the combination shrinks tumors and how …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New Bladder-Saving cancer treatment shows promise
Disease control OngoingThis study is testing a treatment plan for muscle-invasive bladder cancer that aims to avoid major surgery. It combines chemotherapy, an immunotherapy drug (toripalimab), and radiation therapy to try to eliminate the cancer while preserving the patient's bladder. The main goals a…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Study aims to zap cancer, spare healthy tissue
Disease control OngoingThis large trial is testing if doctors can safely shrink the area they target with radiation for patients with advanced nasopharyngeal cancer (a type of head and neck cancer). All patients get chemotherapy first, then are randomly assigned to have radiation aimed at either their …
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Double-Action drug joins fight against tough esophageal cancer
Disease control OngoingThis study is testing whether adding a new immunotherapy drug called cadonilimab to standard chemotherapy and radiation can better control locally advanced esophageal cancer that cannot be surgically removed. The trial will enroll 46 patients to see if this combination improves s…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Surgical technique tested to prevent dangerous bowel paralysis after rectal cancer surgery
Disease control OngoingThis study is testing whether closing the pelvic lining during minimally invasive rectal cancer surgery helps prevent bowel paralysis after the operation. Researchers are comparing two approaches—closing the lining versus leaving it open—in 516 patients across multiple hospitals.…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New Triple-Threat attack on advanced liver cancer shows promise
Disease control OngoingThis study compares two treatment approaches for advanced liver cancer that has spread into a major vein. Researchers want to see if adding a specialized liver chemotherapy to a two-drug immunotherapy and targeted therapy combination helps patients live longer. The trial involves…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Boosting the Body's defenses: new drug aims to help lung cancer patients tolerate tough treatment
Disease control OngoingThis study is testing if adding a drug called thymosin alpha 1 helps people with a specific type of advanced lung cancer complete a full year of follow-up immunotherapy. The immunotherapy is given after initial chemotherapy and radiation. Researchers will compare two groups of pa…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New drug cocktail tested to shrink tumors before esophageal cancer surgery
Disease control OngoingThis study is testing a combination of two immunotherapy drugs with two chemotherapy drugs as a treatment given before surgery for locally advanced esophageal cancer. The goal is to see if this 'neoadjuvant' approach can shrink or even eliminate the tumor, making surgery more eff…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Could glaucoma eye drops halt worsening vision in severe nearsightedness?
Disease control OngoingThis study is testing whether using medication to lower pressure inside the eye can slow down the progression of severe, worsening nearsightedness in adults. Researchers want to see if this treatment can stop the eyeball from getting longer, which is the main cause of vision prob…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
New hope for brain cancer: drug combo trial aims to slow tumor growth
Disease control OngoingThis study is testing if adding a new drug called anlotinib to the standard first treatment (the Stupp regimen) helps people with newly diagnosed glioblastoma live longer without their cancer getting worse. It's a Phase 2 trial involving 150 adults, where participants are randoml…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
New attack on liver cancer: testing a powerful drug duo with targeted artery treatments
Disease control OngoingThis trial is testing a combination of two approved drugs (toripalimab and bevacizumab) with three different procedures that deliver treatment directly into the liver's arteries. The goal is to see which combined approach works best to shrink tumors and control advanced liver can…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope for cervical cancer patients when standard immunotherapy stops working
Disease control OngoingThis study is testing whether a combination of two drugs, zimberelimab and lenvatinib, can help control advanced cervical cancer that has continued to grow despite prior immunotherapy. It aims to see if this combination is safe and effective for up to 30 women whose cancer has pr…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 23, 2026 15:29 UTC
-
New Triple-Threat attack on tough pancreatic cancer
Disease control OngoingThis study is testing a new combination of three drugs as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination is safe and can shrink tumors or slow their growth. It will involve about 32 patients w…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New drug combo trial offers hope for aggressive blood cancer
Disease control OngoingThis study is testing whether adding the immunotherapy drug Sintilimab to a standard chemotherapy regimen is safe and effective for people newly diagnosed with an advanced form of a rare and aggressive blood cancer called NK/T-cell lymphoma. The trial will enroll 34 adults to see…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New Triple-Threat treatment trial targets tough head & neck cancer
Disease control OngoingThis study is testing a new three-drug combination as the first treatment for people whose nasopharyngeal cancer (a type of head and neck cancer) has returned or spread to other parts of the body. The treatment involves taking two medications (anlotinib and capecitabine) and rece…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Triple-Threat attack on spreading head & neck cancer
Disease control OngoingThis study is testing a three-part treatment for nasopharyngeal cancer that has spread to a few other areas in the body. It combines a type of immunotherapy (PD-1 antibody), chemotherapy, and very precise, high-dose radiation (SBRT). The goal is to see if this combination can bet…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
New hope for inoperable esophageal cancer? drug combo trial underway
Disease control OngoingThis study is testing whether adding a drug called apatinib to standard cancer treatment helps people with advanced esophageal cancer that cannot be removed by surgery. About 170 participants will be randomly assigned to receive the standard treatment alone or the standard treatm…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC
-
New scan aims to spot stroke risk before it strikes
Diagnosis ENROLLING_BY_INVITATIONThis study is testing a new ultrasound-based scoring system to better predict which people with plaque buildup in their neck arteries are most likely to have a stroke or heart attack. Researchers will look back at past patient data and also follow new patients to see if this meth…
Sponsor: Sun Yat-sen University • Aim: Diagnosis
Last updated Mar 31, 2026 12:11 UTC
-
Spinal shot aims to ease agony after colon cancer surgery
Symptom relief ENROLLING_BY_INVITATIONThis study is testing if a small dose of morphine injected into the spine before surgery can better control pain and improve recovery for patients having laparoscopic colon cancer surgery. It will compare this method against standard pain management in 252 patients. The main goal…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Mar 23, 2026 15:15 UTC
-
Doctors track heart health to predict cancer treatment outcomes
Knowledge-focused OngoingThis study observes how heart function changes in lung cancer patients receiving combined chemotherapy, radiation, and immunotherapy. Researchers measure heart performance during walking tests to see if these measurements can predict treatment side effects and survival outcomes. …
Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated Apr 02, 2026 02:11 UTC